# Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

> **NCT04645953** · PHASE2 · COMPLETED · sponsor: **Alexza Pharmaceuticals, Inc.** · enrollment: 150 (actual)

## Conditions studied

- Cyclic Vomiting Syndrome

## Interventions

- **COMBINATION_PRODUCT:** 3mg AZ-010
- **COMBINATION_PRODUCT:** 1mg AZ010
- **COMBINATION_PRODUCT:** Staccato Placebo

## Key facts

- **NCT ID:** NCT04645953
- **Lead sponsor:** Alexza Pharmaceuticals, Inc.
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-05
- **Primary completion:** 2022-07-26
- **Final completion:** 2022-07-26
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04645953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04645953, "Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04645953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*